Medivir spins out the antiviral compound MIV-606 to Epiphany
Under the terms of the agreement Medivir will receive equity in Epiphany, milestone payments of maximally USD 24.5m and royalty from world wide sales except the Nordic countries where Medivir has retained the marketing rights for all disease indications. Epiphany will be responsible for the further clinical development of MIV-606.
Phase IIa studies have shown MIV-606 to be efficacious and safe in patients with shingles, caused by the varicella zoster virus (VZV). According to Medivir, the market for zoster drugs is going to increase with the aging population. MIV-606 is also a potent inhibitor of other herpesviruses increasingly implicated in various diseases such as mononucleosis, chronic fatigue syndrome, multiple sclerosis and the development of HIV/AIDS.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.